<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="89875"><TitleDisplay>Study of the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects</TitleDisplay><TitleOfficial>A Phase I, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">9766-CL-0041</Identifier><Identifier type="NCT">NCT01657890</Identifier></Identifiers><Indications><Indication id="124">Fungal infection</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>isavuconazonium chloride/sulfate (oral), Basilea/Astellas</Name><Drug id="36495">isavuconazonium chloride/sulfate (oral), Basilea/Astellas</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="36495">isavuconazonium chloride/sulfate (oral), Basilea/Astellas</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1037956">Astellas Pharma Global Development Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="28104">Basilea Pharmaceutica International Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="36495" type="Drug"><TargetEntity id="281150" type="siDrug">Isavuconazole</TargetEntity><TargetEntity id="311257" type="siDrug">Isavuconazonium sulfate</TargetEntity></SourceEntity><SourceEntity id="1037956" type="Company"><TargetEntity id="5035314387" type="organizationId">Astellas Pharma Global Development Inc</TargetEntity></SourceEntity><SourceEntity id="28104" type="Company"><TargetEntity id="5035524212" type="organizationId">Basilea Pharmaceutica International AG</TargetEntity></SourceEntity><SourceEntity id="124" type="ciIndication"><TargetEntity id="10017533" type="MEDDRA"></TargetEntity><TargetEntity id="D009181" type="MeSH"></TargetEntity><TargetEntity id="-2109353222" type="omicsDisease"></TargetEntity><TargetEntity id="817" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="777" type="Action"><TargetEntity id="444" type="Mechanism">Lanosterol 14alpha-demethylase Inhibitors</TargetEntity><TargetEntity id="5607" type="Mechanism">Sterol 14-alpha Demethylase (CYP51) (Trypanosoma cruzi) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1037956">Astellas Pharma Global Development Inc</Company></CompaniesSponsor><CompaniesCollaborator><Company id="28104">Basilea Pharmaceutica International Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="777">Lanosterol-14 demethylase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="161">Ergosterol synthesis inhibitor</Class><Class id="1748">Fungicide</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>28</PatientCountEnrollment><PatientCountEvaluable>48</PatientCountEvaluable><DateStart>2012-06-30T00:00:00Z</DateStart><DateEnd type="actual">2013-01-31T00:00:00Z</DateEnd><DateChangeLast>2019-06-12T12:04:07Z</DateChangeLast><DateAdded>2012-08-08T13:10:27Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Astellas Pharma Global Development</Affiliation><Name>Medical Director</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects are healthy, non-elderly males and females between 18 and 45 years and
             healthy, elderly males and females &gt;/= 65 years of age&lt;/li&gt;&lt;li&gt;The subject has a body weight of at least 45 kg and has a body mass index (BMI) of 18
             to 32 kg/m2, inclusive&lt;/li&gt;&lt;li&gt;The estimated (calculated) creatinine clearance must be within the age-appropriate
             normal range, if abnormal, the abnormality is not clinically significant, as
             determined by the investigator&lt;/li&gt;&lt;li&gt;Results for aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and
             total bilirubin must be within the normal range&lt;/li&gt;&lt;li&gt;The female subject  agrees  to sexual abstinence, or is surgically sterile,
             post-menopausal (defined as at least two years at screening without menses), or using a
             medically acceptable double-barrier method (eg, spermicide and diaphragm, or
             spermicide and condom) to prevent pregnancy and agree to continue using this method
             from screening until 3 weeks after the follow-up visit at the end of the study; and
             is not lactating or pregnant as documented by negative pregnancy tests at screening
             and day -1&lt;/li&gt;&lt;li&gt;The male subject agrees to sexual abstinence, is surgically sterile, or is using a
             medically acceptable method to prevent pregnancy and agrees to continue using this
             method from screening until 3 weeks after the follow-up visit at the end of the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac
             arrhythmia or torsade de pointes, structural heart disease, or family history of long
             QT syndrome (suggested by sudden death of a close relative at a young age due to
             possible or probable cardiac causes)&lt;/li&gt;&lt;li&gt;The subject has a positive result for hepatitis C antibodies, hepatitis B surface
             antigen at screening or is known to be positive for human immunodeficiency virus
             (HIV)&lt;/li&gt;&lt;li&gt;The subject has a known or suspected allergy to any of the components of the trial
             products including the azole class of compounds, or a history of multiple and/or
             severe allergies to drugs or foods (as judged by the investigator), or a history of
             severe anaphylactic reactions&lt;/li&gt;&lt;li&gt;The subject is a smoker (any use of tobacco or nicotine containing products) within 6
             months prior to screening&lt;/li&gt;&lt;li&gt;The subject, if non-elderly, has had treatment with prescription drugs or
             complementary and alternative medicines within 14 days prior to day -1, or
             over-the-counter medications within 1 week prior to day -1, with the exception of
             acetaminophen up to 2 g/day&lt;/li&gt;&lt;li&gt;The subject, if elderly, has not been on stable concomitant medications (minor
             necessary dosing changes are acceptable) for at least 4 weeks prior to study drug
             administration or is taking any medication that would interfere with the evaluation
             of &lt;ulink linkType="Drug" linkID="36495"&gt;isavuconazole&lt;/ulink&gt; in this study (CYP3A4 inducer or inhibitor)&lt;/li&gt;&lt;li&gt;The subject has a recent history (within the last two years) of drug or alcohol abuse,
             as defined by the investigator, or a positive drug and/or alcohol screen&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pharmacokinetics (PK) variables for isavuconazole (in plasma): AUCinf, AUClast, and Cmax: area under the concentration-time curve from time of dosing to infinity (AUCinf), area under the concentration-time curve from time of dosing to the last quantifiable concentration (AUClast) and maximum concentration (Cmax)</Description><Timeframe>Day 1: pre-dose, 0.5, 1, 1.5, 2, 3, 4 ,6, 8, 10, 12, 16, 20, 24, 36, 48, 72, 120, 168, 240, 288, 336 h post-dose on day 1</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>PK variables for isavuconazole (in plasma): Vz/F, CL/F, t1/2, tmax: apparent volume of distribution (Vz/F), apparent body clearance after oral dosing  (CL/F), apparent terminal elimination half-life (t1/2), time to attain maximum concentration (tmax)</Description><Timeframe>Day 1: pre-dose, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 ,36, 48, 72, 120, 168, 240, 288, 336 h post-dose on day 1</Timeframe></Measure><Measure><Description>Safety assessed by recording adverse events, laboratory assessments, physical examinations, vital signs, electrocardiograms (ECGs)</Description><Timeframe>Days 1 to 15</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In May 2019, results were published. Higher exposures in elderly females were not associated with significant toxicity or treatment-emergent adverse events, as measured in this study [&lt;ulink linkType="Reference" linkID="2161720"&gt;2161720&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the pharmacokinetics of &lt;ulink linkType="Drug" linkID="36495"&gt;isavuconazonium sulfate&lt;/ulink&gt; in healthy
      non-elderly and elderly male and female subjects.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In May 2019, results were published. Based on the population pharmacokinetic analysis, elderly females had the highest exposure versus males (ratio of total area under the time-concentration curve [AUC], 138) and versus nonelderly females (ratio of AUC, 147) [&lt;ulink linkType="Reference" linkID="2161720"&gt;2161720&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Study population: healthy non-elderly male and female subjects(age 18 to 45 years); healthy elderly male and female subjects (age &gt;/= 65 years).&lt;br/&gt;All subjects would receive a single-dose of &lt;ulink linkType="Drug" linkID="36495"&gt;isavuconazonium sulfate&lt;/ulink&gt; on day 1 under fasting conditions.
      Subjects would be  confined to study center from day -1 until 4 when they are discharged.
      Subjects would return for out-patient visits on days 6, 8, 11, 13 and 15. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;All subjects received a single oral dose of 372 mg of isavuconazonium sulfate (equivalent to 200 mg isavuconazole) [&lt;ulink linkType="Reference" linkID="2161720"&gt;2161720&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="224283">isavuconazonium chloride/sulfate (oral), Basilea/Astellas</Intervention><Treatments><Treatment><Dose>372 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Parexel International</Name><Address1>Glendale</Address1><Address2>California</Address2><Address3>91206</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01657890</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-08-02T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-08-08T13:10:27Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>